Skip to Content

Belluscura lists on London exchange

Belluscura lists on London exchange

LONDON and PLANO, Texas – Belluscura, a medical device developer focused on lightweight and portable oxygen enrichment technology, has begun trading on the Alternative Investment Market (AIM) on the London Stock Exchange under the ticker symbol BELL. 

The company has raised 17.5 million pounds supported by new and existing inventors, and it has a market cap of about 50.96 million pounds. 

SPARK Advisory Partners Limited acted as the Belluscura’s sole nominated adviser and Dowgate Capital Limited acted as sole broker and bookrunner. 

The company’s first product, the X-PLO2R, is a lightweight POC cleared by the U.S. Food and Drug Administration and designed to replace larger, metal oxygen tanks and heavier POCs. Belluscura plans to launch that device, along with the X-PLO2R CX and DX POCs, within the next 12 months in the United States. Following a soft launch, the company plans to appoint distributors in the second half of 2021 and into 2022. It will then pursue International Regulatory clearances in 2021-22 before expanding distribution globally. 

Belluscura either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.


To comment on this post, please log in to your account or set up an account now.